MNDR

Business Context and Reporting Period

Company: Mobile-Health Network Solutions (MNDR)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Jurisdiction: Cayman Islands (Headquartered in Singapore)
Business Overview: A leading telehealth solutions provider in Singapore operating the MaNaDr ecosystem. The company offers teleconsultations, e-commerce for health products (MaNaShop), B2B pharmaceutical sales (MaNaPharma), and corporate wellness services (MaNaCare). Operations span Singapore, Vietnam, Malaysia, and Indonesia.

Key Financial Metrics

Note: The filing text does not provide a specific "2024 Q4" breakdown; data reflects the full fiscal year ended June 30, 2025.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by 45.3% to $7.6 million, primarily driven by a $6.1 million drop in telemedicine revenue. Private telemedicine transactions fell 49.5% year-over-year.
• Cost Reduction: Operating expenses decreased significantly by 73.5% to $4.8 million. This was largely due to a 95.5% reduction in share-based compensation (from $9.1 million to $0.4 million) and lower IPO-related professional fees.
• Improved Loss Profile: Net loss narrowed by 78.3% to $3.4 million, despite the revenue decline, due to the substantial reduction in non-cash share-based compensation and operating costs.
• Cash Position: Cash and cash equivalents dropped by approximately $5.7 million to $1.0 million, reflecting net cash used in operating activities of $4.4 million and investing activities of $2.4 million.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

Management plans to utilize a Standby Equity Purchase Agreement (SEPA) and an At-The-Market (ATM) offering to raise capital. Strategies include expanding user engagement through AI-driven tools, implementing blockchain for data storage, and expanding into new APAC markets. The company intends to retain earnings for operations and expansion, with no plans to pay dividends.

Material Risks and Contingencies

• Going Concern: The independent auditor has issued an explanatory paragraph regarding "Going Concern." Recurring losses and negative operating cash flows raise substantial doubt about the company's ability to continue as a going concern without additional financing.
• Regulatory Action: In August 2024, the Singapore Ministry of Health (MOH) directed "Manadr Clinic @Citygate" to temporarily suspend outpatient teleconsultation services under the Healthcare Services Act (HCSA). While management initially assessed this as immaterial, further regulatory actions remain a risk.
• License Revocation: The MOH revoked Manadr Clinic Pte Ltd's license to provide outpatient medical services effective December 20, 2024.
• Generative AI Risks: The company highlights risks related to data breaches, bias, and regulatory uncertainty regarding its integration of Generative AI.
• Share Consolidation: The company executed a 1-for-8 share consolidation in February 2025 and a 1-for-5 consolidation in September 2025 (subsequent event).

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $1.0 million cash balance against the $4.4 million annual operating cash burn rate.
• Capital Raising Status: Confirm the execution and proceeds from the SEPA (up to $10 million) and the new ATM agreement (up to $300 million) to address the going concern warning.
• Regulatory Compliance: Investigate the current status of the suspended Manadr Clinic @Citygate and the impact of the revoked license on the B2B and telemedicine segments.
• Revenue Sustainability: Assess the reasons for the 49.5% drop in private telemedicine transactions and the viability of the recovery strategy.
• Share Structure: Confirm the impact of the recent 1-for-5 reverse stock split on share price and liquidity.